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Abstract
Background: Whether the combination of antimicrobial therapy is a factor in mortality in Pseudomonas aeruginosa
bacteremia remains to be elucidated. This study investigated the risk factors for mortality in P. aeruginosa bacteremia
patients and the influence of adequate antimicrobial therapy and combination therapy on clinical outcomes.
Methods: This retrospective study analyzed data of 234 patients with P. aeruginosa bacteremia at a 1,200-bed tertiary
teaching university hospital in South Korea between January 2010 and December 2012. Factors associated with
mortality were determined. Mortality was compared in patients with adequate empirical and targeted combination
therapy, and monotherapy, and inappropriate therapy.
Results: A total of 141 (60.3%) patients were given appropriate empirical antibiotic treatment (combination therapy in
38 and monotherapy in 103). Among 183 patients (78.2%) who finally received appropriate targeted treatment, 42 had
combination therapy and 141 had monotherapy. The percentage of patients receiving empirical combination therapy
was slightly, but not significantly higher, in the survivor group than in the nonsurvivor group (17.0% [31/182] vs. 13.5%
[7/52], p = 0.74). A similar tendency was demonstrated for targeted combination therapy (19.8% [36/182] vs.
11.5% [6/52], respectively; p = 0.31). However, in a subgroup analysis of data from patients (n = 54) with an absolute
neutrophil count less than 500/mm3, the patients who had appropriate empirical or targeted combination therapy
showed better outcomes than those who underwent monotherapy or inappropriate therapy (p < 0.05). Mechanical
ventilation (odds ratio [OR], 6.93; 95% confidence interval [CI], 2.64–18.11; p = 0.0001), the use of a central venous
catheter (OR, 2.95; 95% CI, 1.35–6.43; p = 0.007), a high Acute Physiology and Chronic Health Evaluation II score
(OR, 4.65; 95% CI, 1.95–11.04; p = 0.0001), and presence of septic shock (OR, 2.91; 95% CI, 1.33–6.38; p = 0.007)
were independent risk factors for 14-day mortality.
Conclusions: Disease severity was a critical factor for mortality in our patients with P. aeruginosa bacteremia.
Overall, combination therapy had no significant effect on 14-day mortality compared with monotherapy. However,
appropriate combination therapy showed a favorable effect on survival in patients with febrile neutropenia.
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Background
Pseudomonas aeruginosa represents a common cause of
nosocomial infection. Immunocompromised patients such
as those with malignancy or neutropenia are at high risk
of bacteremia, and P.aeruginosa is one of the commonly
isolated pathogens associated with bacteremia in such
patients [1,2]. Despite advances in antimicrobial therapy,
P.aeruginosa infection remains associated with high mor-
tality ranging of 18% - 61% [3].
The therapeutic options for P. aeruginosa infection are
limited owing to the intrinsic resistance of the bacterium
to commonly used antibiotics and the increase in multi-
drug resistance. The use of more than one kind of anti-
biotic has been known to be effective for certain patients;
the use of a combination of at least two drugs was demon-
strated to have a synergistic or additive effect in lowering
the risk of receiving an inappropriate empirical therapy,
and to prevent the emergence of resistant organisms [4].
Some studies reported that a combination therapy in pa-
tients with gram-negative bacteremia resulted in better
outcomes than monotherapy [5,6]. However, the effects of
combination therapies for P. aeruginosa infection remain
unclear.
The risk factors for mortality in patients with bacteremia
are reported to be severe sepsis, neutropenia, and multi-
drug resistance [7-10]. Whether the adequacy of anti-
microbial therapy is a factor for mortality in P. aeruginosa
bacteremia remains to be elucidated [7,11-13]. In this
study, we identified the risk factors for mortality and in-
vestigated the effect of the adequacy of antimicrobial ther-
apy in patients with P. aeruginosa bacteremia. We also
analyzed and compared the effects of combination therapy
and monotherapy on 14-day mortality.
Methods
Study design
A retrospective study was performed on data from patients
(>18 years old) with confirmed clinical signs of P. aerugi-
nosa infection between January 2010 and December 2012
at a 1200-bed tertiary teaching hospital in South Korea.
P. aeruginosa was isolated from at least one set of blood
cultures of samples collected from the patients. Only
the first bacteremia episode in each patient was in-
cluded in this study. We assessed the severity of under-
lying disease using the Acute Physiology and Chronic
Health Evaluation (APACHE) II scoring system and the
Charlson comorbidity index. We used 14-day overall mor-
tality as the main outcome for the assessment of mortality
in patients.
Empirical antimicrobial therapy was defined according
to the initial antimicrobial therapy regimens that were
administered within 24 hours after blood culture samples
were obtained, and before results of susceptibility tests
were known. Targeted antimicrobial therapy was defined
as specific antibiotics given within 24 hours after the re-
sults of antimicrobial susceptibility. Antimicrobial therapy
was considered appropriate when the strain showed
in vitro susceptibility to the antibiotics administered,
and the dosages of the drugs were adequate according to
current guidelines [14]. An appropriate combination ther-
apy was defined if two or more antibiotics showed in vitro
susceptibility. Appropriate monotherapy was defined as
treatment with only one active antibiotic. Aminoglycoside
monotherapy was also defined as inadequate therapy.
Neutropenia was defined as an absolute neutrophil count
(ANC) < 500/mm3 at the time of bacteremia. Multidrug
resistance was defined when the strain was resistant to
three or more antipseudomonal anti-microbial categories
(ciprofloxacin, ceftazidime, piperacillin/tazobactam, mero-
penem, and amikacin) [15,16]. Infection was assessed ac-
cording to the criteria established by the Centers for
Disease Control and Prevention, and patients were consid-
ered to have contracted the infection when P. aeruginosa
was isolated from a sterile site in patients with definite
clinical signs of infection [17]. Septic shock was defined in
the published guidelines [18].
Microbiological examination
Identification of P. aeruginosa in blood samples was per-
formed using a VITEK 2 automated system (bioMérieux,
Marcy l’Etoile, France). Susceptibility results were inter-
preted according to the guidelines established by the
Clinical and Laboratory Standards Institute [19]. Carba-
penem resistance was defined as nonsusceptibility to
meropenem and/or imipenem in vitro, and isolates with
intermediate resistance were regarded as resistant.
Statistically analysis
The Student t-test or the Mann–Whitney U test were
used for analysis of continuous variables, and the χ2 test
or Fisher’s exact test were used for categorical variables.
Multivariate analysis using multiple logistic regression
was performed for statistically significant factors in the
univariate analysis to determine the risk factors associated
with 14-day overall mortality. Statistical analysis was per-
formed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA), and
p < 0.05 was considered statistically significant.
Ethical statement
This study was approved by the institutional review board
of Seoul St. Mary’s Hospital, Seoul (KC14RISI0033).
Results
Demographic characteristics
During the study period, a total of 234 patients (92 male,
142 female) with P.aeruginosa bacteremia were included.
The most common underlying disease was malignancy
(n = 68, 29.1%), followed by hypertension (n = 52, 22.2%)
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and diabetes mellitus (n = 47, 20.1%). P. aeruginosa re-
sistance to carbapenem was found in 50.4% (n = 118) of
patients. The presumed sources of bacteremia were the
respiratory tract (n = 70, 29.9%), abdominal cavity (n = 42,
17.9%), urinary tract (n = 18, 7.7%), postoperative wound
(n = 11, 4.7%), vascular catheter (n = 4, 1.7%), and other un-
known sources (n = 89, 38%). The overall 14-day mortality
was 22.2% (n = 52), and almost half (n = 25) died within
24 hours after the onset of bacteremia.
Table 1 shows the comparison of the demographic
characteristics of the survivors and nonsurvivors. Neu-
tropenia was more frequent among the patients who
died than among those who survived (34.6% [18/52] vs.
19.8% [36/182], p = 0.02). Nonsurvivors showed a higher
APACHE II score (18 vs. 11, p = 0.0001) and had a higher
rate of septic shock (53.8% [28/52] vs. 18.7% [34/182],
p = 0.0001) than the survivors. The use of a central venous
catheter (69.2% [36/52] vs. 33.5% [61/182], p = 0.0001),
foley catheter (53.8% [28/52] vs. 12.1% [22/182], p =
0.0001) and mechanical ventilator (38.5% [20/52] vs.
6.6%[12/182], p = 0.0001) was significantly more frequent
among the nonsurvivors than among the survivors.
In the univariate analysis, 14-day mortality was as-
sociated with neutropenia (odds ratio [OR], 2.14; 95%
Table 1 Comparison of demographic characteristics of survivors and non survivors of Pseudomonas aeruginosa
bacteremia
Total (n = 234) Non survivors (n = 52) Survivors (n = 182) P value
Age, median years (range) 57 (19 ~ 93) 60.5 (19 ~ 84) 56 (21 ~ 93) 0.35
Male sex 92 (39.3%) 23 (44.2%) 69 (37.9%) 0.41
Underlying disease
Diabetes mellitus 47 (20.1%) 8 (15.4%) 39 (21.4%) 0.34
Hypertension 52 (22.2%) 11 (21.2%) 41 (22.5%) 0.83
Liver cirrhosis 13 (5.6%) 2 (3.8%) 11 (6.0%) 0.54
Transplant 34 (14.5%) 10 (19.2%) 24 (13.2%) 0.27
Solid organ 8 (3.4%) 1 (1.9%) 7 (3.8%)
Bone marrow 26 (11.1%) 9 (17.3%) 17 (9.3%)
Malignancy 68 (29.1%) 14 (26.9%) 54 (29.7%) 0.70
Dialysis 11 (4.7%) 2 (3.8%) 9 (4.9%) 0.74
Neutropenia 54 (23.1%) 18 (34.6%) 36 (19.8%) 0.02
Hospitalization in the preceding 90 days 98 (41.9%) 26 (50.0%) 72 (39.6%) 0.18
APACHE II score, median (IQR) 12 (0 ~ 40) 18 (5 ~ 40) 11 (0 ~ 28) 0.0001
Charlson comobidity index, median (IQR) 3 (0 ~ 13) 4 (1 ~ 10) 4 (0 ~ 13) 0.57
Septic shock 62 (26.7%) 28 (53.8%) 34 (18.7%) 0.0001
Invasive procedure
Central venous catheter 97 (41.5%) 36 (69.2%) 61 (33.5%) 0.0001
Surgical drainage 39 (16.7%) 8 (15.4%) 31 (17.0%) 0.78
Foley catheter 50 (21.4%) 28 (53.8%) 22 (12.1%) 0.0001
Mechanical ventilator 32 (13.7%) 20 (38.5%) 12 (6.6%) 0.0001
The length of stay before bacteremia, median days (IQR) 1 (0 ~ 92) 1 (0 ~ 28) 2.5 (0 ~ 92) 0.2
Source of bacteremia 0.006
Pneumonia 70 (29.9%) 27 (51.9%) 43 (23.6%)
Urinary tract 18 (7.7%) 2 (3.8%) 16 (8.8%)
Vascular catheter-related 4 (1.7%) 1 (1.9%) 3 (1.6%)
Intra-abdomen 42 (17.9%) 7 (13.5%) 35 (19.2%)
Postoperative wound 11 (4.7%) 1 (1.9%) 10 (5.5%)
Unknown 89 (38.0%) 14 (26.9%) 75 (41.2%)
Length of hospital stay, median days (IQR) 17 (1 ~ 364) 12 (1 ~ 364) 18 (1 ~ 92) 0.08
Carbapenem resistance 118 (50.4%) 26 (50.0%) 92 (50.5%) 0.94
Multidrug resistance 6 (2.6%) 3 (5.8%) 3 (1.6%) 0.09
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confidence interval [CI], 1.09–4.22; p = 0.03), the use of
a mechanical ventilator (OR, 8.85; 95% CI, 3.94–19.88;
p = 0.0001), the use of a central venous catheter (OR, 4.46;
95% CI, 2.29–8.67; p = 0.0001), a high APACHE II score
(OR, 8.88; 95% CI, 4.06–19.38; p = 0.0001), and the
presence of septic shock (OR, 5.08; 95% CI, 2.63–9.83;
p = 0.0001) (Table 2). The multivariate analysis revealed
that the use of a mechanical ventilator (OR, 6.93; 95% CI,
2.64–18.11; p = 0.0001), the use of a central venous cath-
eter (OR, 2.95; 95% CI, 1.35–6.43; p = 0.007), a high APA-
CHE II score (OR, 4.65; 95% CI, 1.95–11.04; p = 0.0001),
and the presence of septic shock (OR, 2.91; 95% CI, 1.33–
6.38; p = 0.007) were the independent risk factors for
14-day mortality (Table 2).
A total of 141 (60.3%) patients were given appropriate
empirical antibiotic treatment, which included combin-
ation therapy in 38 patients (16.2%) and monotherapy in
103 patients (44.0%). Among 183 patients (78.2%) who
were finally treated with appropriate appropriate targeted
treatment, 42 (17.9%) were given combination therapy
and 141 (60.3%) were given monotherapy. Table 3 de-
scribes the administered adequate antibiotics in detail.
Adequate empirical antimicrobials used in monotherapy
were as follows: 88 β-lactam, 8 fluoroquinolone, and 7
colistin, whereas targeted monotherapy consisted of 114
β-lactam, 20 fluoroquinolone, and 7 colistin. β-lactam
and aminoglycoside was the most frequent combination
in patients treated with adequate empirical combination
Table 2 Risk factors associated with 14-day mortality in patients with P. aeruginosa bacteremia
Univariate analysis Multivariate analysis
Risk factor OR 95% CI P value OR 95% CI P value
Age > 60 (years) 1.42 0.77-2.64 0.26
Neutropenia 2.14 1.09-4.22 0.03 1.45 0.63-3.33 0.37
Mechanical ventilator 8.85 3.94-19.88 0.0001 6.93 2.64-18.11 0.0001
Central venous catheter 4.46 2.29-8.67 0.0001 2.95 1.35-6.43 0.007
APACHE II score≥ 13 8.88 4.06-19.38 0.0001 4.65 1.95-11.04 0.0001
Septic shock 5.08 2.63-9.83 0.0001 2.91 1.33-6.38 0.007
Carbapenem resistance 1.02 0.55-1.89 0.94
Multidrug resistance 3.65 0.72-18.67 0.12
Pneumonia as a source of bacteremia 1.01 0.51-2.01 0.96
Empirical therapy
Appropriate combination therapy 0.82 0.31-2.14 0.69
Appropriate monotherapy 1.17 0.59-2.28 0.64
Inappropriate therapy 1.0 (ref)
Targeted therapy
Appropriate combination therapy 0.44 0.37-1.61 0.49
Appropriate monotherapy 0.78 0.15-1.27 0.13
Inappropriate therapy 1.0 (ref)
OR = odd rations; CI = confidential interval; CR = carbapenem-resistance.
Table 3 Description of administered antibiotics in
patients receiving adequate treatment
Adequate monotherapy
Empirical (n = 103) Targeted (n = 141)
ß-lactam 88 (85.4%) 114 (80.9%)
Antipseudomonal
penicillin
24 (23.3%) 31 (21.9%)
Cephalosporin 45 (43.7%) 36 (25.5%)
Carbapenem 19 (18.4%) 47 (33.3%)
Fluoroquinolones 8 (7.8%) 20 (14.2%)
Colistin 7 (6.8%) 7 (4.9%)
Adequate combination therapy
Empirical (n = 38) Targeted (n = 42)
ß-lactam + aminoglycosides 32 (84.2%) 33 (78.6%)
Antipseudomonal
penicillin
6 (68.4%) 25 (59.6%)
Cephalosporin 26 (15.8%) 3 (7.1%)
Carbapenem 0 5 (11.9%)
ß-lactam + fluoroquinolones 5 (13.2%) 7 (16.7%)
Antipseudomonal
penicillin
3 (7.9%) 2 (4.8%)
Cephalosporin 2 (5.3%) 4 (9.5%)
Carbapenem 0 1 (2.4%)
Colistin + fluoroquinolones 1 (2.6%) 1 (2.4%)
Colistin + aminoglycoside 0 1 (2.4%)
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therapy (84.2% [32/38]), and in adequate targeted com-
bination therapy (78.6% [33/42]). The appropriateness of
empirical therapy was not significantly different between
the survivor and nonsurvivor groups (61.5% [32/52] vs.
60.4% [110/182], p = 0.89), and the appropriateness of
targeted therapy was also not different between the two
groups (73.1% [38/52] vs. 79.7% [145/182], p = 0.31).
Patients with P.aeruginosa bacteremia who received
combination empirical therapy or targeted therapy did
not show better outcomes than those who receivied
monotherapy or inadequate therapy (Table 4). The per-
centage of patients receiving empirical combination
therapy was slightly, but not significantly higher, in the
survivor group than in the nonsurvivor group (17.0%
[31/182] vs. 13.5% [7/52], p = 0.74). A similar tendency
was found in the group receiving targeted therapy (19.8%
[36/182] vs. 11.5% [6/52], respectively; p = 0.31). How-
ever, a subgroup analysis of data from patients (n = 54)
with an ANC < 500/mm3 indicated that that those who
underwent appropriate empirical combination therapy
showed better outcomes than those who underwent
appropriate empirical monotherapy or inappropriate ther-
apy (p = 0.001). In addition, patients who underwent ap-
propriate targeted combination therapy also showed a
more favorable outcome than those who underwent ap-
propriate targeted monotherapy or inappropriate therapy
(p = 0.01) (Table 4).
Discussion
The effect of appropriate therapies and combination
therapies on mortality in patients with P. aeruginosa
bacteremia remains to be clarified. In this study, the
overall in-hospital 14-day mortality rate in the patients
with P. aeruginosa bacteremia was as high as 22.2%.
The independent predictors for mortality among pa-
tients with P. aeruginosa bacteremia were the use of a
mechanical ventilator, the use of a central venous cath-
eter, a high APACHE II score, and a clinical presentation
of septic shock. We did not demonstrate a beneficial ef-
fect of adequate empirical or targeted combination ther-
apy on survival, although there was a tendency towards a
protective effect on mortality. However, in the subgroup
with neutropenia, adequate empirical or targeted com-
bination therapy was associated with a significantly lower
14-day mortality rate. The condition of patients with
P. aeruginosa bacteremia deteriorated rapidly, and most
nonsurvivors died on the day of onset. Therefore, early
appropriate treatment plays an important role in the out-
come among P. aeruginosa bacteremia patients, and
some studies have reported that inappropriate antibiotic
therapy is associated with poor prognosis [11,20]. There
are several reports that a clinical presentation of sepsis
is a strong predictor of mortality consistent with the
present study [7,13,21]. As neutropenia may be a factor
for increased mortality in patients with hematologic or
solid malignancy, we analyzed the relationship between
adequacy of antibiotic therapy and mortality after strati-
fying the cases in our study according to the presence of
neutropenia [10,22]. Our results demonstrated that ad-
equate combination antimicrobial therapy was associated
with a decreased mortality rate in patients with neutro-
penia. Combination therapy is advantageous in terms of
preventing the emergence of resistant organisms, its syn-
ergistic effect, and its ability to increase the likelihood of
organisms being susceptible to at least one of the compo-
nent antibiotics [4]. A meta-analysis by Safdar et al. dem-
onstrated that combination therapy could reduce the
mortality rate in patients with P. aeruginosa infection;
however, another study indicated that combination ther-
apy did not affect patient outcomes [21,23]. There is con-
troversy whether combination therapy for P. aeruginosa
is superior to monotherapy in improving the survival of
Table 4 Comparison of outcomes according to adequacy of antibiotics
Survivor (n = 182) Non survivor (n = 52) P value
All patients (n = 234) Empirical Combination 31 (17.0%) 7 (13.5%) 0.74
Monotherapy 78 (42.9%) 25 (48.1%)
Inappropriate 31 (17.0%) 7 (13.5%)
Targeted Combination 36 (19.8%) 6 (11.5%) 0.31
Monotherapy 109 (59.9%) 32 (61.5%)
Inappropriate 37 (20.3%) 14 (26.9%)
Patients with neutropenia (n = 54) Empirical Combination 19 (52.7%) 4 (22.2%) 0.001
Monotherapy 16 (44.4%) 7 (38.8%)
Inadequate 1 (2.7%) 7 (38.8%)
Targeted Combination 21 (58.3%) 10 (55.5%) 0.01
Monotherapy 14 (38.8%) 3 (16.7%)
Inadequate 1 (2.7%) 5 (27.7%)
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the patients with P. aeruginosa bacteremia. Our study
showed that combination therapy may have a significant
beneficial effect in a subgroup of patients with neutro-
penia One meta-analysis showed that there was no
significant difference between ß-lactam-aminoglycoside
combination therapy and monotherapy in patients with
febrile neutropenia, however the analysis did not target
only patients with P. aeruginosa infection, and did not in-
vestigate the adequacy of antimicrobial therapy [24]. Our
results are consistent with those of a prospective obser-
vational study that reported that combination therapy
was beneficial only in neutropenic patients, although the
study included patients with Gram-negative bacteremia,
and not specifically P. aeruginosa infection [25]. We sug-
gest that combination empirical therapy should be con-
sidered for febrile neutropenic patients, if there is a risk
of Pseudomonas infection. In our non-neutropenic pa-
tients, combination therapy for P. aeruginosa bacteremia
did not appear to confer a significant additional beneficial
effect, and disease severity such as the presence of septic
shock and high APACHE II score played an important
role in the treatment outcome.
In our study, approximately 50% of all patients were
infected with carbapenem-resistant P. aeruginosa, indi-
cating a high prevalence of antibiotic resistance in our
hospital compared with the approximately 30% preva-
lence rate reported for the general Korean population
[26]. Recently, cases of carbapenem resistance of gram-
negative isolates have been increasing, as in our hospital
[26]. The high prevalence of cases is likely the result of
our hospital population, including a high percentage of
malignancy cases and transplant recipients. Carbapenem
resistance or multidrug resistance was not an independent
factor for higher 14-day mortality in our study. There is
some controversy with regard to the effect of antibiotic re-
sistance on mortality. Some studies have reported that the
clinical presentation or the use of appropriate antibiotics,
rather than resistance, were predictors of mortality in pa-
tients with P. aeruginosa bacteremia [27,28]. Further stud-
ies are required to clarify this point.
The major limitation of this study was its retrospective
nature in a single center and diversity of underlying dis-
ease and condition of bacteremia. Second, the choice of
antibiotics depended on the physician’s opinion, which
could be a source of bias. We did not analyze outcome
based on the antibiotic administered. Third, appropriate
therapy was defined as the administration of antibiotics
to which the isolate had in vitro susceptibility. In our
study, colistin monotherapy was defined as adequate if
P. aeruginosa was susceptible to colistin in vitro. Colistin
has been reintroduced for the treatment of multidrug re-
sistant Gram-negative bacilli infections, and there have
been reports of the synergy of colistin combined with
other antibiotics [29]. However, it remains questionable
in clinical practice whether colistin monotherapy is inferior
to combination therapy in patients with P. aeruginosa
infection, especially multidrug-resistant species.
Conclusion
The mortality rate of P. aeruginosa bacteremia remains
high, despite advances in antibiotic therapy. High
APACHE II score and presence of septic shock was the
critical factor for mortality in P. aeruginosa bacteremia,
and combination therapy did not significantly reduce the
overall 14-day mortality rate. However, in cases with fe-
brile neutropenia, combination therapy showed a benefi-
cial effect on survival, and early appropriate combination
treatment was associated with a positive effect on patient
outcomes.
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